Home/Specialty/Drug Monograph

Metoclopramide

sam

Metoclopramide

Therapeutic Class
Prokinetic and Antiemetic

Subclass
Dopamine D2 Receptor Antagonist

Speciality
Gastroenterology

Schedule (India)
Schedule H

Routes
Oral, Intramuscular (IM), Intravenous (IV)

Formulations

Tablet: 5 mg, 10 mg
Injection: 5 mg/mL (2 mL ampoules)
Oral solution/syrup: 5 mg/5 mL

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India):

1. Nausea and Vomiting (post-operative, drug-induced, uremic, radiation-induced)
Route	Starting Dose	Titration	Usual Maintenance Dose	Maximum Dose	Clinical Notes
Oral/IM/IV	10 mg	Not required	10 mg TID (30 mg/day)	30 mg/day	Administer 30 minutes before meals and at bedtime if TID dosing

Key Points:

Give 30 minutes before meals when used for meal-related nausea
For acute vomiting: single 10 mg dose IM or IV
Limit duration to shortest period necessary (typically 5–7 days for acute episodes)

2. Gastroparesis (including diabetic gastroparesis)

• Starting dose: 10 mg orally, 30 minutes before each meal and at bedtime (QID)
• Titration: None usually required; assess clinical response at 2–4 weeks
• Usual maintenance dose: 10 mg QID (before meals and bedtime)
• Maximum dose: 40 mg/day
• Duration: Limit to ≤12 weeks due to tardive dyskinesia risk; reassess need at 4–6 week intervals

Clinical consideration: In diabetic patients, improved gastric emptying may affect glycemic control and insulin requirements—monitor blood glucose.

3. Migraine-Associated Nausea (adjunct to analgesics)

• Route: IV or IM preferred
• Dose: 10 mg as single dose at onset of nausea/vomiting
• Titration: Not applicable
• Maximum dose: 10 mg per episode; may repeat after 6–8 hours if needed (max 30 mg/day)
• Notes:

Enhances gastric emptying and improves oral analgesic absorption
May be given alongside NSAIDs or specific migraine therapies
IV administration: give as slow push over 1–2 minutes

Secondary Indications — Adults (Off-label, if any):

• Chemotherapy-Induced Nausea/Vomiting (CINV) — low to moderate emetogenic chemotherapy

Dose: 10–20 mg IV, administered 30 minutes before chemotherapy
Duration: Single dose before each chemotherapy cycle, or TID during chemotherapy days
Specialist only: Oncologist/medical oncologist
OFF-LABEL (as monotherapy; more commonly used as adjunct to 5-HT3 antagonists)
Evidence basis: Indian oncology supportive care protocols; commonly used in resource-limited settings when newer antiemetics unavailable

• Functional Dyspepsia with Delayed Gastric Emptying

Dose: 10 mg orally TID, 30 minutes before meals
Duration: Short-term (4–6 weeks); reassess need and consider alternative therapies
OFF-LABEL for functional dyspepsia without proven gastroparesis
Evidence basis: Indian gastroenterology practice; API Textbook of Medicine references use in dysmotility-like dyspepsia

• Facilitating Small Bowel Intubation (diagnostic procedures)

Dose: 10 mg IV as single dose before procedure
OFF-LABEL in current Indian practice, though historically used
Evidence basis: Older Indian hospital protocols

Paediatric indications

PAEDIATRIC DOSING (Specialist Only)

Primary Indications:

1. Nausea and Vomiting (post-operative, chemotherapy-associated)
Age/Weight	Route	Dose	Frequency	Maximum Daily Dose	Maximum Duration
1–18 years (≥10 kg)	Oral/IV/IM	0.1–0.15 mg/kg per dose	Up to TID	0.5 mg/kg/day (max 30 mg/day)	5 days
<1 year or <10 kg	NOT RECOMMENDED except under pediatric specialist supervision	—	—	—	—

Safety Monitoring:

High risk of extrapyramidal symptoms (EPS) in children and adolescents
Observe closely for dystonic reactions, especially within first 24–48 hours
Have diphenhydramine or benztropine available for acute dystonia
Use lowest effective dose for shortest duration

Secondary Indications — Paediatrics (Off-label, if any):

• Chemotherapy-Induced Nausea (adjuvant to primary antiemetics)

Dose: 0.1–0.15 mg/kg IV, 30 minutes before chemotherapy
Duration: Single dose or short course during chemotherapy days
Specialist only: Pediatric oncologist
OFF-LABEL
Evidence basis: IAP supportive care protocols for pediatric oncology; commonly used when 5-HT3 antagonists not available

• Gastroesophageal Reflux Disease (GERD) in Infants

NOT RECOMMENDED in current Indian pediatric practice
OFF-LABEL and associated with significant neurological adverse effects
Evidence basis: IAP and WHO no longer support routine use; safer alternatives (e.g., positioning, feed thickening, H2-blockers if needed) preferred
Avoid except in very specific situations under pediatric gastroenterologist guidance

Renal Adjustments

Required in renal impairment — Metoclopramide and metabolites accumulate; reduce dose and/or frequency:

eGFR (mL/min/1.73m²)	Dose Adjustment	Frequency Adjustment
≥60	No adjustment	No adjustment
40–59	Reduce dose by 25%	Standard frequency (TID-QID)
20–39	Reduce dose by 50%	BID or TID maximum
<20 or on hemodialysis	Reduce dose by 75%	Once daily or BID maximum

Hemodialysis: Metoclopramide is minimally dialyzed; give dose after dialysis on dialysis days.

Peritoneal dialysis: Reduce dose by 75%; give once daily.

Hepatic adjustment

• Mild impairment (Child-Pugh A): No dose adjustment usually required

• Moderate impairment (Child-Pugh B):

Start at lower end of dose range (5 mg per dose)
Monitor closely for CNS effects and EPS
Consider reducing frequency to BID

• Severe hepatic impairment (Child-Pugh C):

Avoid unless benefit clearly outweighs risk
Specialist supervision required
Risk of hepatic encephalopathy exacerbation and increased CNS adverse effects

Contraindications

Pheochromocytoma — risk of hypertensive crisis due to catecholamine release

• Previous tardive dyskinesia related to metoclopramide use

• Mechanical gastrointestinal obstruction, perforation, or active GI hemorrhage — prokinetic effect may worsen these conditions

• Parkinson's disease or parkinsonian syndromes — dopamine antagonism worsens extrapyramidal symptoms

• Known hypersensitivity to metoclopramide or excipients

• Epilepsy or seizure disorders (relative contraindication) — may lower seizure threshold

Cautions

• Elderly patients: Increased risk of extrapyramidal symptoms, cognitive impairment, sedation, and falls

• Cardiac conduction abnormalities: Risk of QT interval prolongation, particularly with IV use or in combination with other QT-prolonging agents

• Concomitant use with other dopamine antagonists (antipsychotics, some antiemetics) — additive risk of EPS and tardive dyskinesia

• Depression or history of suicidal ideation: Rare reports of worsening depression; monitor mental status

• Avoid chronic use beyond 12 weeks: Risk of tardive dyskinesia increases with duration; document clear indication if use exceeds this period

• Hypertension: May cause transient increase in blood pressure (rare)

• Patients with NADH-cytochrome b5 reductase deficiency: Risk of methemoglobinemia

• Young adults (18–30 years): Higher risk of dystonic reactions compared to middle-aged adults

Pregnancy

Overall Assessment: Generally considered safe for short-term use; widely used in Indian obstetric practice for nausea and vomiting

Risk Category:

Not formally classified in Indian regulatory system
US FDA former Category B (animal studies show no risk; adequate human studies lacking)
Large observational studies show no increased teratogenic risk

When It May Be Used:

Nausea and vomiting of pregnancy when dietary/lifestyle measures fail
Hyperemesis gravidarum (though other agents may be preferred first-line)
Short-term use (days to few weeks) preferred
All trimesters: appears safe based on available data

Preferred Alternatives in Indian Obstetric Practice:

First-line: Doxylamine + pyridoxine (when available)
Alternatives: Ondansetron (though first-trimester use debated), vitamin B6, ginger
Antihistamines (promethazine, cyclizine)

Monitoring:

Monitor for extrapyramidal symptoms in mother (rare but reported)
No specific fetal monitoring required for metoclopramide use alone
If used near term, observe neonate for potential EPS (very rare)

Lactation

Compatibility: Generally compatible with breastfeeding

Drug Levels in Breast Milk:

Metoclopramide enters breast milk in low concentrations
Milk-to-plasma ratio approximately 0.5–2
Estimated infant dose: 1–10% of maternal weight-adjusted dose

Potential Galactagogue Effect:

Metoclopramide increases prolactin secretion
Sometimes used OFF-LABEL to enhance milk production (not standard Indian practice; specialist use only)

Monitoring in Infant:

Watch for sedation, irritability, or changes in feeding pattern
Monitor for dystonic reactions (very rare)
Diarrhea (occasional report)

Preferred Alternatives (if needed):

For nausea: Ondansetron generally preferred if antiemetic needed in lactating mother
For reflux/dyspepsia: Antacids, H2-blockers, or PPIs usually safe

Clinical Recommendation: Can be used during breastfeeding for standard short-term indications; use lowest effective dose

Elderly

Starting Dose:

Begin with 5 mg per dose (rather than standard 10 mg)
Particularly important in patients >70 years or frail elderly

Titration:

Slower and more cautious
Assess response and tolerance after 3–5 days before increasing
Maximum dose in elderly: 20 mg/day unless clear indication requires higher (specialist decision)

Extra Risks in Elderly:

Extrapyramidal symptoms: Higher incidence, including parkinsonism, akathisia, dystonia
Tardive dyskinesia: Risk increases with age and duration of use
Cognitive effects: Confusion, sedation more common
Orthostatic hypotension: Increased fall risk
Reduced renal clearance: Many elderly have reduced eGFR even with normal serum creatinine (use Cockcroft-Gault or eGFR calculation).

Monitoring:

Assess for involuntary movements before and during therapy
Monitor for falls, gait disturbance, confusion
Limit duration to minimum necessary (avoid chronic use)

Route Considerations:

Prefer oral route when feasible
If IM required, ensure patient mobile/assisted to reduce orthostatic hypotension risk

Major drug interactions

Levodopa and Other Dopaminergic Antiparkinson Agents

Mechanism: Metoclopramide antagonizes dopamine; directly opposes levodopa effect
Effect: Loss of antiparkinson efficacy; worsening of Parkinson symptoms
Action: AVOID combination; use alternative antiemetic (e.g., domperidone with caution, ondansetron)

Antipsychotics (typical and atypical)

Mechanism: Additive dopamine antagonism
Effect: Increased risk of severe extrapyramidal symptoms, neuroleptic malignant syndrome, tardive dyskinesia
Action: Avoid or use with extreme caution; specialist supervision required

QT-Prolonging Agents (e.g., erythromycin, clarithromycin, haloperidol, sotalol, amiodarone, ondansetron, quinolones)

Mechanism: Additive QT prolongation
Effect: Risk of torsades de pointes, particularly with IV metoclopramide
Action: Avoid combination if possible; if essential, baseline and monitoring ECG required; correct electrolytes

MAO Inhibitors (rarely used in India, but includes linezolid)

Mechanism: Risk of hypertensive crisis, especially in presence of undiagnosed pheochromocytoma
Effect: Severe hypertension, serotonin syndrome (theoretical)
Action: Avoid combination; use alternative antiemetic

Anticholinergic Agents (e.g., atropine, dicyclomine, trihexyphenidyl)

Mechanism: Direct pharmacological antagonism
Effect: Reduced prokinetic efficacy of metoclopramide
Action: Avoid concurrent use when treating gastroparesis or dysmotility

Moderate drug interactions

Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonergic Agents

Increased risk of serotonin syndrome (rare) and additive EPS risk
Monitor for tremor, restlessness, confusion if combined
Usually can be used together with monitoring

CNS Depressants (benzodiazepines, opioids, sedating antihistamines, alcohol)

Additive sedation and drowsiness
Counsel patient about activities requiring alertness
Consider dose reduction of one or both agents

Digoxin

Metoclopramide may reduce digoxin absorption (accelerated gastric emptying reduces dissolution time)
Monitor digoxin levels if used chronically together
Usually not clinically significant with normal formulations

Cyclosporine

Metoclopramide increases rate of cyclosporine absorption (faster gastric emptying)
May result in higher peak levels
Monitor cyclosporine trough levels; dose adjustment rarely needed

Insulin and Oral Hypoglycemic Agents

Accelerated gastric emptying may alter glucose absorption kinetics
Risk of hypoglycemia in diabetic gastroparesis patients when gastric emptying improves
Monitor blood glucose more frequently when initiating metoclopramide in diabetics

Hepatotoxic Drugs (e.g., anti-TB drugs, azoles)

Additive hepatotoxicity risk (metoclopramide rarely hepatotoxic)
Monitor liver function if prolonged co-administration

Bromocriptine, Cabergoline (dopamine agonists)

Metoclopramide may reduce efficacy (dopamine antagonism)
Usually manageable; monitor clinical response

Common Adverse effects

• Drowsiness and fatigue (10–20% of patients)

• Restlessness and akathisia (motor restlessness, inability to sit still; 5–10%)

• Diarrhea or loose stools (prokinetic effect; 5–10%)

• Headache

• Dizziness

• Insomnia or sleep disturbances (paradoxical in some patients)

• Asthenia (weakness)

• Extrapyramidal symptoms (dystonia, parkinsonism, akathisia — more common in young adults and elderly; 1–10% depending on population)

Serious Adverse effects

• Tardive Dyskinesia

Potentially irreversible involuntary movements (tongue protrusion, lip smacking, choreiform movements)
Risk increases with duration of use (especially >12 weeks) and cumulative dose
Higher risk in elderly, women, and diabetics
Action: Discontinue immediately if signs develop; symptoms may persist or worsen after stopping

• Neuroleptic Malignant Syndrome (NMS)

Rare but life-threatening: hyperthermia, muscle rigidity, altered mental status, autonomic instability
Action: Discontinue immediately; hospitalize; supportive care

• Acute Dystonic Reactions

Sudden onset (usually within 24–48 hours): torticollis, oculogyric crisis, opisthotonus, tongue protrusion
More common in children, young adults, and with IV administration
Action: IV/IM diphenhydramine (1 mg/kg or 25–50 mg) or benztropine (1–2 mg); symptoms resolve rapidly

• QT Prolongation and Cardiac Arrhythmias

Torsades de pointes reported, especially with IV use, high doses, or in combination with other QT-prolonging drugs
Action: Monitor ECG in at-risk patients; correct electrolytes

• Seizures

Rare; may occur in patients with prior seizure history or in overdose
Action: Discontinue; manage seizures per standard protocol

• Depression, Suicidal Ideation

Rare case reports; monitor patients with psychiatric history
Action: Discontinue if mood changes emerge

• Methemoglobinemia

Very rare; risk higher in NADH-cytochrome b5 reductase deficiency, infants, or with overdose
Presents with cyanosis, dyspnea, altered mental status
Action: Methylene blue if clinically significant (methemoglobin >20–30%)

• Hyperprolactinemia

Galactorrhea, gynecomastia, menstrual irregularities with chronic use
Usually reversible upon discontinuation

Monitoring requirements

Baseline (before initiating therapy):

Neurological examination: check for any pre-existing movement disorders, tremor, rigidity
ECG if patient has cardiac risk factors, conduction abnormalities, on other QT-prolonging drugs, or if IV metoclopramide planned
Renal function (serum creatinine, eGFR) — especially in elderly
Exclude mechanical GI obstruction clinically (and radiologically if uncertain) before using for gastroparesis or dyspepsia

After Initiation / Dose Change:

Monitor for extrapyramidal symptoms within first 24–72 hours (especially in children, young adults)
Assess for sedation, dizziness, orthostatic symptoms (particularly elderly)
Evaluate symptom response (nausea control, gastric emptying improvement)

During Ongoing Therapy:

Short-term use (<5–7 days): Minimal monitoring; observe for acute EPS
Prolonged use (>2 weeks):
- Reassess indication and need for continuation every 2–4 weeks
- Monitor for involuntary movements at each visit (early tardive dyskinesia signs)
- If duration approaches or exceeds 12 weeks: document clear rationale and discuss risk/benefit with patient; consider alternative therapies

Laboratory Monitoring (if prolonged use):

Renal function if elderly or renal impairment present
Liver function tests if on other hepatotoxic drugs
Electrolytes (potassium, magnesium) if on diuretics or other QT-prolonging agents
Serum prolactin if symptoms of hyperprolactinemia

Special Populations:

Diabetics on insulin: monitor blood glucose more frequently when starting (improved gastric emptying may alter glucose dynamics)

Brands in India

• Perinorm® (IPCA Laboratories)
• Reglan® (Alkem Laboratories)
• Maxolon® (RPG Life Sciences)
• Maxeron® (Glenmark Pharmaceuticals)
• Emekon® (Micro Labs)
• Metpure® (Mankind Pharma)
• Metopar® (Zuventus Healthcare)
• Emitil® (Win-Medicare)
• Multiple generic formulations widely available

Fixed-Dose Combinations (examples):

Metoclopramide + Paracetamol (e.g., for migraine)
Metoclopramide + Simethicone (for bloating/dyspepsia)
Note: Use of FDCs should follow rational prescribing; monotherapy preferred when possible

Price range (INR)

• Tablet 10 mg: ₹1.50–₹5 per tablet (strip of 10: ₹15–₹50)

• Injection 5 mg/mL (2 mL ampoule): ₹4–₹12 per ampoule

• Oral syrup/solution 5 mg/5 mL: ₹20–₹40 per 60 mL bottle; ₹35–₹60 per 100 mL bottle

Pricing Notes:

Generic formulations at lower end of range
Branded products (Perinorm, Reglan, etc.) at mid-to-upper range
Not included in National List of Essential Medicines (NLEM) 2022 — not under NPPA price control
Available in government hospitals and primary health centers; often dispensed free or at minimal cost

Clinical pearls

1. Route and Timing Matter for Efficacy:

For nausea/vomiting with oral intolerance: prefer IM or IV route initially
For gastroparesis/dysmotility: oral route 30 minutes before meals optimizes prokinetic effect
In migraine: IV/IM not only treats nausea but enhances absorption of subsequently given oral analgesics (NSAIDs, triptans)

2. Extrapyramidal Risk Stratification:

Highest risk: Children, adolescents, young adults (18–30 years), elderly, females
Acute dystonia (within hours to 2 days): Have diphenhydramine or promethazine readily available, especially when using IV metoclopramide in young patients
Tardive dyskinesia (after weeks to months): Irreversible in many cases — strictly limit duration to <12 weeks

3. Always Exclude Mechanical Obstruction:

Before prescribing for "gastroparesis" or persistent vomiting, ensure no bowel obstruction (clinical exam, consider imaging if red flags)
Metoclopramide in mechanical obstruction can worsen perforation risk

4. IV Administration Technique:

Give as slow IV push over 1–3 minutes (not rapid bolus)
Rapid injection increases risk of akathisia, anxiety, and transient hypotension
Can also dilute in 50 mL NS and infuse over 15 minutes to minimize adverse effects

5. Not First-Line for All Nausea:

For chemotherapy-induced nausea: 5-HT3 antagonists (ondansetron, granisetron) are more effective for moderate-high emetogenic chemo; metoclopramide adjunct or alternative in resource-limited settings
For pregnancy nausea: try dietary measures, ginger, vitamin B6 first; then doxylamine+pyridoxine if available; metoclopramide if others fail or unavailable

6. Switching from Metoclopramide:

If prolonged use needed (chronic gastroparesis): consider domperidone (less CNS penetration, lower EPS risk but has cardiac QT concerns) or other prokinetics under specialist guidance
If EPS emerge: stop metoclopramide immediately; do not rechallenge

7. Documentation for Chronic Use:

If prescribing beyond 12 weeks (exceptional cases): document clear indication, failure of alternatives, patient informed of tardive dyskinesia risk, and regular reassessment plan in medical record